FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2979509332> ?p ?o ?g. }

• W2979509332 abstract "Abstract Abstract 4998 Purpose Prevalence of patients (pts) suffering of non-Hodgkin's lymphoma (NHL) and diabetes is increasing. Previous investigations were mainly focused on possible association with an increased risk of NHL in pts with type 2 diabetes. In another way, it is well known that NHL patients (pts) with co-morbidity are treated less intensively and have worse prognosis. We propose a retrospective analysis of a homogeneous aggressive lymphoma cohort based on a multicentric regional network database to assess the cross-impact of diabetes and NHL in term of pts management and survival. Patients and methods All pts with high-grade NHL cases, histologically proven, diagnosed between 2003 and 2008 in the Hematology Department of regional network HEMATOLIM, have been included. Diabetes of type 2 has been defined according to international criteria. Data about diabetes and lymphoma treatments, toxicity, relapse, progression or death, have been collected from the Database Structure Régionale de Référence sur les Lymphomes en Limousin. Statistical analysis had been done by StatView and SAS 9.1.2 softwares. Results We included 251 NHL pts with aggressive NHL concerning 69.3% Diffuse Large B Cell Lymphoma (DLBCL) (n=174), 7.6% Mantle cell (n=19), 5.2% Peripheral T-cell (n=13), 5.2% Burkitt (n=13) and 12.7% others (anaplastic (n=9), Follicular grade 3B (n=8),T angioimmunoblastic (n=8), primary mediastinal NHL (n=3), nasal NK-T (n=2), T-cell-rich BCL (n=1), centroblastic BCL (n=1)). Among these NHL, 16.7% had type 2 diabetes (n=42). Sex ratio was 1 for diabetic pts (dp) versus (vs) 1.4 for non-diabetic pts (ndp), the average age was 65.1±15.8, 71.3±8.4 for dp vs 63.8±16.6 for ndp (p=0.005). All received first-line chemotherapy mainly Cyclophosphamide/Oncovin/ Adriamycine/Prednisone ± Rituximab (54.6%, n=137), with no difference between dp and ndp (respectively 59.5% vs 57.0%). Chemo-resistance was reported for 22.7% of pts (28.6% dp (n=12) and 21.5% ndp (n=45)). Chemotherapy-related toxicities were more frequent in dp (71.4%, n=30, vs 47.8%, n=100 ndp) (p=0.005), mainly fever and/or bleeding and infectious complications or back to hospitalization. Dose reductions were more frequent in dp, 31.0%, (n=13) vs ndp 12.0%, n=25) (p=0.0017) and adjustements in time-interval (54.8%, n=23, vs 38.8%, n=81 ndp) (p=0.05) of chemotherapy course. A logistic regression analysis showed that dose reductions and treatment-related toxicities were associated to diabetes status (p=0.015 and p=0.026, respectively). Complete remission (CR) was achieved for 66% ndp (n=138) vs 40.5% dp (n=17) with significant difference (p=0.0019). Relapses: no significant difference between both groups with 13.9% ndp (n=29) vs 19% dp (n=8). Mortality rate was significantly increased: 41.6 % ndp vs 59.5% dp (p=0.033), mainly due to NHL complications, 41.6% ndp (n=87) vs 59.5% dp (n=25) (p=0.033). With a median follow-up of 17 months (m) (range 0-72), median overall survival (OS) was not reached for ndp vs 12±9 m for dp (p=0.006), median event-free survival (EFS) was 41±6.2 m for ndp vs 11±4.3 m for dp (p=0.002). In a multivariate analysis, the differences disappeared on OS and EFS after adjustment on age. A logistic regression analysis showed an important increasing of complications, adjustment of doses, and CR but these chemotherapy-related toxicities had no impact on dp survival. The impact of chemotherapy mainly including corticosteroids on the long term diabetes status has been assessed at the end of NHL treatment, 35.7% increased oral medication to oral insulin or received an intensified dose of the antidiabetic treatment (9.5%, n=4). Some dp with oral treatment improved their glycemia (7.1%, n=3), and used only hygiene-dietary measures. Long term insulin treatment was introduced after glycemia disorders for 3.8% ndp (n=8). Conclusion Aggressive NHL were more frequently associated with type 2 diabetes (16%) in our regional cohort probably due to the study population median age around 68 years. A real impact of incidence of the chemotherapy-related toxicities, back to hospitalization, a less dose-intensity chemotherapy on dp CR has been significantly demonstrated. EFS and OS were not significant in multivariate analysis especially with adjustment on age. These results claim for a cautious management of diabetes at the initial assessment and during chemotherapy for decreasing complications and by an intensive patient education. Disclosures No relevant conflicts of interest to declare." @default.
• W2979509332 created "2019-10-18" @default.
• W2979509332 creator A5002143829 @default.
• W2979509332 creator A5005139468 @default.
• W2979509332 creator A5023004938 @default.
• W2979509332 creator A5024987845 @default.
• W2979509332 creator A5026625329 @default.
• W2979509332 creator A5040147996 @default.
• W2979509332 creator A5050467722 @default.
• W2979509332 creator A5053031492 @default.
• W2979509332 creator A5061700845 @default.
• W2979509332 creator A5078049492 @default.
• W2979509332 creator A5086884689 @default.
• W2979509332 creator A5087582064 @default.
• W2979509332 date "2009-11-20" @default.
• W2979509332 modified "2023-09-26" @default.
• W2979509332 title "“Non-Hodgkin's Lymphomas and Diabetes of Type 2 in Elderly Patients: Impact On Management in the Real Life”." @default.
• W2979509332 doi "https://doi.org/10.1182/blood.v114.22.4998.4998" @default.
• W2979509332 hasPublicationYear "2009" @default.
• W2979509332 type Work @default.
• W2979509332 sameAs 2979509332 @default.
• W2979509332 citedByCount "0" @default.
• W2979509332 crossrefType "journal-article" @default.
• W2979509332 hasAuthorship W2979509332A5002143829 @default.
• W2979509332 hasAuthorship W2979509332A5005139468 @default.
• W2979509332 hasAuthorship W2979509332A5023004938 @default.
• W2979509332 hasAuthorship W2979509332A5024987845 @default.
• W2979509332 hasAuthorship W2979509332A5026625329 @default.
• W2979509332 hasAuthorship W2979509332A5040147996 @default.
• W2979509332 hasAuthorship W2979509332A5050467722 @default.
• W2979509332 hasAuthorship W2979509332A5053031492 @default.
• W2979509332 hasAuthorship W2979509332A5061700845 @default.
• W2979509332 hasAuthorship W2979509332A5078049492 @default.
• W2979509332 hasAuthorship W2979509332A5086884689 @default.
• W2979509332 hasAuthorship W2979509332A5087582064 @default.
• W2979509332 hasConcept C126322002 @default.
• W2979509332 hasConcept C134018914 @default.
• W2979509332 hasConcept C143998085 @default.
• W2979509332 hasConcept C177713679 @default.
• W2979509332 hasConcept C2777180221 @default.
• W2979509332 hasConcept C2779338263 @default.
• W2979509332 hasConcept C2992779791 @default.
• W2979509332 hasConcept C555293320 @default.
• W2979509332 hasConcept C71924100 @default.
• W2979509332 hasConcept C74909509 @default.
• W2979509332 hasConceptScore W2979509332C126322002 @default.
• W2979509332 hasConceptScore W2979509332C134018914 @default.
• W2979509332 hasConceptScore W2979509332C143998085 @default.
• W2979509332 hasConceptScore W2979509332C177713679 @default.
• W2979509332 hasConceptScore W2979509332C2777180221 @default.
• W2979509332 hasConceptScore W2979509332C2779338263 @default.
• W2979509332 hasConceptScore W2979509332C2992779791 @default.
• W2979509332 hasConceptScore W2979509332C555293320 @default.
• W2979509332 hasConceptScore W2979509332C71924100 @default.
• W2979509332 hasConceptScore W2979509332C74909509 @default.
• W2979509332 hasLocation W29795093321 @default.
• W2979509332 hasOpenAccess W2979509332 @default.
• W2979509332 hasPrimaryLocation W29795093321 @default.
• W2979509332 hasRelatedWork W145700531 @default.
• W2979509332 hasRelatedWork W1971859602 @default.
• W2979509332 hasRelatedWork W2022927507 @default.
• W2979509332 hasRelatedWork W2040320318 @default.
• W2979509332 hasRelatedWork W2263204970 @default.
• W2979509332 hasRelatedWork W2272309561 @default.
• W2979509332 hasRelatedWork W2297910408 @default.
• W2979509332 hasRelatedWork W2343604562 @default.
• W2979509332 hasRelatedWork W2401044898 @default.
• W2979509332 hasRelatedWork W2408467984 @default.
• W2979509332 hasRelatedWork W2414612161 @default.
• W2979509332 hasRelatedWork W2424375541 @default.
• W2979509332 hasRelatedWork W2475099746 @default.
• W2979509332 hasRelatedWork W2530603159 @default.
• W2979509332 hasRelatedWork W2937055621 @default.
• W2979509332 hasRelatedWork W2943727467 @default.
• W2979509332 hasRelatedWork W2947120476 @default.
• W2979509332 hasRelatedWork W3000577850 @default.
• W2979509332 hasRelatedWork W3121405945 @default.
• W2979509332 hasRelatedWork W196809261 @default.
• W2979509332 isParatext "false" @default.
• W2979509332 isRetracted "false" @default.
• W2979509332 magId "2979509332" @default.
• W2979509332 workType "article" @default.